Cohort 1 patients with advanced-stage disease
Survival curves for 234 patients stratified by means of BEV added to
chemotherapy or chemotherapy alone are illustrated in Figure 1.The median PFS duration was greater in the subgroup with chemotherapy
plus BEV than with chemotherapy alone (11.6 m versus 9.3 m, P = 0.325;
HR 0.84, 95% CI, 0.6–1.19) among advanced-stage patients
(Figure 1A) , similar to that found among ICON7-defined
high-risk patients (10.5 m versus 6.0 m, P = 0.035; HR 0.62, 95% CI,
0.39–0.97) (Figure 1B) . The median OS was not achieved in the
subgroup with BEV and was 43.7 m in those without BEV (P = 0.123; HR
0.69, 95% CI, 0.43–1.11) among advanced-stage patients (Figure
1A) ; similar results were seen among ICON7-defined high-risk patients
(not reached versus 34.7 m, P = 0.101; HR 0.61, 95% CI, 0.33–1.10)
(Figure 1B) . Compared to patients with chemotherapy alone,
among ICON7-defined high-risk patients, patients with BEV throughout had
a significantly greater PFS (17.6 m; P = 0.005; HR 0.39, 95% CI,
0.20–0.75) and OS (not reached; P = 0.010; HR 0.22, 95% CI,
0.07–0.72) (Figure 1D) . However, among advanced-stage
patients, patients with BEV throughout had a significantly greater OS
(not reached; P = 0.030; HR 0.41, 95% CI, 0.18–0.93), but not PFS,
than those with chemotherapy alone (Figure 1C ).
Advanced-stage patients treated with chemotherapy plus BEV in the
subgroup of PFI <6 m had a significantly greater PFS (P =
0.001), but not OS (Figure S2) . No statistical difference in
the impacts of BEV on PFS or OS between clear cell and serous histology
was observed in the early or advanced stage (Figure S3) .